Accès gratuit
Numéro
Med Sci (Paris)
Volume 23, Numéro 11, Novembre 2007
Page(s) 991 - 996
Section M/S revues
DOI https://doi.org/10.1051/medsci/20072311991
Publié en ligne 15 novembre 2007
  1. Oleske J, Minefor A, Cooper R, et al. Immune deficiency syndrome in children. JAMA 1983; 249 : 2345–9.
  2. Cowan MJ, Hellmann D, Chudwin D, et al. Maternal transmission of acquired immune deficiency syndrome. Pediatrics 1984; 73 : 382–6.
  3. Lapointe N, Michaud J, Pekovic D, et al. Transplacental transmission of HTLV-III virus. N Engl J Med 1985; 312 : 1325–6.
  4. UNAIDS. AIDS epidemic update : December 2006. Genève, Suisse : UNAIDS, 2006.
  5. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5 : 558–67.
  6. Shafran SD. Early initiation of antiretroviral therapy : the current best way to reduce liver-related deaths in HIV/hepatitis C virus-coinfected patients. J Acquir Immune Defic Syndr 2007 online (sois presse).
  7. Lagaye S, Derrien M, Menu E, et al. European network for the study of in utero transmission of HIV-1. Cell-to-cell contact results in a selective translocation of maternal human immunodeficiency virus type 1 quasispecies across a trophoblastic barrier by both transcytosis and infection. J Virol 2001; 75 : 4780–91.
  8. Tscherning-Casper C, Papadogiannakis N, Anvret M, et al. The trophoblastic epithelial barrier is not infected in full-term placentae of human immunodeficiency virus-seropositive mothers undergoing antiretroviral therapy. J Virol 1999; 73 : 9673–8.
  9. Mundy DC, Schinazi RF, Gerber AR, et al. Human immunodeficiency virus isolated from amniotic fluid. Lancet 1987; 2 : 459–60.
  10. Tuomala RE, O’Driscoll PT, Bremer JW, et al. Cell-associated genital tract virus and vertical transmission of human immunodeficiency virus type 1 in antiretroviral-experienced women. J Infect Dis 2003; 187 : 375–84.
  11. Mandelbrot L, Burgard M, Teglas JP, et al. Frequent detection of HIV-1 in the gastric aspirates of neonates born to HIV-infected mothers. AIDS 1999; 13 : 2143–9.
  12. Thiry L, Sprecher-Goldberger S, Jonckheer T, et al. Isolation of virus from cell free breast milk of three healthy virus carriers. Lancet 1985; 2 : 891–2.
  13. Rousseau CM, Nduati RW, Richardson BA, et al. Longitudinal analysis of human immunodeficiency virus type 1 RNA in breast milk and of its relationship to infant infection and maternal disease. J Infect Dis 2003; 187 : 741–7.
  14. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994; 331 : 1173–80.
  15. Perinatal HIV Guidelines Working Group. Public health Service Task Force recommendations for the use of antiretroviral drugs in pregnant HIV-1 infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States. Bethesda, MD : National Institutes of Health, 2006.
  16. Soudeyns H, Yao XJ, Gao Q, et al. Anti-HIV-1 activity and in vitro toxicity of 2’-deoxy, 3’-thiacytidine (BCH-189), a novel heterocyclic nucleoside analog. Antimicrob Agents Chemother 1991; 35 : 1386–90.
  17. Rodrigues A, Faucher P, Batallan A, et al. Mode of delivery of HIV-infected women : a retrospective study of 358 pregnancies followed in the same hospital between 2000 and 2004. Gynecol Obstet Fertil 2006; 34 : 304–11.
  18. Guay LA, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda : HIVNET 012 randomized trial. Lancet 1999; 354 : 795–802.
  19. Lallemant M, Jourdain G, Le Coeur S, et al. Single-dose perinatal nevirapine plus standard ziduvudine to prevent mother-to-child transmission of HIV-1 in Thailand. N Engl J Med 2004; 351 : 217–28.
  20. Newell ML, Dunn DT, Peckham CS, Semprini AE, Pardi G. Vertical transmission of HIV-1 : maternal immune status and obstetric factors. The European Collaborative Study. AIDS 1996; 10 : 1675–81.
  21. Plaeger S, Bermudez S, Mikyas Y, et al. Decreased CD8 cell-mediated viral suppression and other immunologic characteristics of women who transmit human immunodeficiency virus to their infants. J Infect Dis 1999; 179 : 1388–94.
  22. Pillay T, Zhang HT, Drijfhout JW, et al. Unique acquisition of cytotoxic T-lymphocyte escape mutants in infant human immunodeficiency virus type 1 infection. J Virol 2005; 79 : 12100–5.
  23. Wu X, Parast AB, Richardson BA, et al. Neutralization escape variants of human immunodeficiency virus type 1 are transmitted from mother to infant. J Virol 2006; 80 : 835–44.
  24. MacDonald KS, Embree J, Njenga S, et al. Mother-child class I HLA concordance increases perinatal human immunodeficiency virus type 1 transmission. J Infect Dis 1998; 177 : 551–6.
  25. Cheynier R, Langlade-Demoyen P, Marescot MR, et al. Cytotoxic T lymphocyte responses in the peripheral blood of children born to human immunodeficiency virus-1-infected mothers. Eur J Immunol 1992; 22 : 2211–7.
  26. Silvestri G, Soudeyns H, Lapointe N, et al. T-cell receptor Vβ-specific expansions in children from HIV-infected mothers. AIDS 1996; 10 : 549–51.
  27. Soudeyns H, Champagne P, Holloway CL, et al. Transient T cell receptor BV-specific expansions of CD4+ and CD8+ T cells during the early phase of pediatric human immunodeficiency virus infection : characterization of expanded cell populations by T cell receptor phenotyping. J Infect Dis 2000; 181 : 107–20.
  28. Safrit JT, Ruprecht R, Ferrantelli F, et al. Immunoprophylaxis to prevent mother-to-child transmission of HIV-1. J Acquir Immune Defic Syndr 2004; 35 : 69–77.
  29. Xu W, Hofmann-Lehmann R, McClure HM, et al. Passive immunization with human neutralizing monoclonal antibodies : correlates of protective immunity against HIV. Vaccine 2002; 20 : 1956–60.
  30. Binley JM, Wrin T, Korber B, et al. Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J Virol 2004; 78 : 13232–52.
  31. Thomas SL, Newell ML, Peckham CS, Ades AE, Hall AJ. A review of hepatitis C virus (HCV) vertical transmission : risks of transmission to infants born to mothers with and without HCV viraemia or human immunodeficiency virus infection. Int J Epidemiol 1998; 27 : 108–17.
  32. Boucher M, Gruslin A, Delage G, et al. The reproductive care of women living with hepatitis C infection – Les soins de santé en reproduction pour les femmes vivant avec l’hépatite C. Health Canada/Santé Canada and/et SOGC Clinical Practice Guidelines / Directives cliniques de la SOGC. J Soc Obstet Gynaecol Can 2000; 22 : 820–44.
  33. Mok J, Pembrey L, Tovo PA, Newell ML, European Paediatric Hepatitis C Virus Network. When does mother to child transmission of hepatitis C virus occur ? Arch Dis Child Fetal Neonatal Ed 2005; 90 : 156–60.
  34. Ioannidis JP, Abrams EJ, Ammann A, et al. Perinatal transmission of human immunodeficiency virus type 1 by pregnant women with RNA virus loads < 1000 copies/ml. J Infect Dis 2001; 183 : 539–45.
  35. King NJ, Maxwell LE, Kesson AM. Induction of class I major histocompatibility complex antigen expression by West Nile virus on gamma interferon-refractory early murine trophoblast cells. Proc Natl Acad Sci USA 1989; 86 : 911–5.
  36. Chi BH, Mudenda V, Levy J, et al. Acute and chronic chorioamnionitis and the risk of perinatal human immunodeficiency virus type 1 transmission. Am J Obs Gynecol 2006; 194 : 174–81.
  37. Lauer GM, Nguyen TN, Day CL et al. Human immunodeficiency type 1-hepatitis C virus co-infection : intraindividual comparison of cellular immune responses against two persistent viruses. J Virol 2002; 76 : 2817–26.
  38. Gervais A, Bacq Y, Bernuau J, et al. Decrease in serum ALT and increase in serum HCV RNA during pregnancy in women with chronic hepatitis C. J Hepatol 2000; 32 : 293–9.
  39. Canobio S, Guilbert C, Troesch M, et al. Differing patterns of liver disease progression and hepatitis C virus (HCV) quasi species evolution in children vertically co-infected with HCV and human immunodeficiency virus type 1. J Clin Microbiol 2004; 42 : 4365–9.
  40. Troesch M, Jalbert E, Canobio S, et al. Characterization of humoral and cell-mediated immune responses directed against hepatitis C virus F protein in patients co-infected with hepatitis C virus and HIV-1. AIDS 2005; 19 : 775–84.
  41. Troesch M, Meunier I, Lapierre P, et al. Study of a novel hypervariable region in hepatitis C virus (HCV) E2 envelope glycoprotein. Virology 2006; 352 : 357–67.
  42. Ferm VH, Willhite C, Kilham L. Teratogenic effects of ribavirin on hamster and rat embryos. Teratology 1978; 17 : 93–101.
  43. Dubois J, Hershon L, Carmant L, et al. Toxicity profile of interferon alfa-2b in children : A prospective evaluation. J Pediatr 1999; 135 : 782–5.
  44. Akouamba BS, Viel J, Charest H, et al. HIV-1 genetic diversity in antenatal cohort, Canada. Emerg Infect Dis 2005; 11 : 1230–4.
  45. Ozaslan E, Yilmaz R, Simsek H, Tatar G. Interferon therapy for acute hepatitis C during pregnancy. Ann Pharmacother 2002; 36 : 1715–8.

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.